QUANTRO Therapeutics
↗Vienna, Austria
QUANTRO Therapeutics is a Vienna-based drug discovery company focused on developing novel therapeutics that interfere with disease-causing transcriptional programs in cancer. The company utilizes its proprietary QUANTROseq® platform, which combines functional genetics, time-resolved RNA sequencing, and comparative transcriptomics to identify and develop inhibitors, modulators, or degraders of transcription factors previously considered undruggable.
Founded in 2019 as a spin-out from the Institute of Molecular Biotechnology (IMBA) and the Research Institute of Molecular Pathology (IMP), the company is supported by key investors including Boehringer Ingelheim Venture Fund and Evotec. QUANTRO maintains a strategic collaboration with Boehringer Ingelheim to develop first-in-class cancer treatments.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2019
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$11M+
Investors:Boehringer Ingelheim Venture Fund (BIVF), Evotec
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery/Preclinical
Modalities:Small molecule
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Boehringer Ingelheim (Strategic R&D collaboration for oncology targets)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Michael Bauer - CEO
Arianna Sabò - Head of Research and Discovery
Scientific Founders:Stefan Ameres, Johannes Zuber
LINKS
Website:quantro-tx.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of QUANTRO Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with QUANTRO Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.